Every parliamentary written question tabled by Stuart Andrew this session, with the full answer and department. Back to the MP page.
Showing 21–40 of 174 · Department of Health and Social Care
What factors his Department is considering before responding to the Joint Committee on Vaccination and Immunisation’s November 2024 advice that the shingles vaccination programme should be expanded to include adults aged 80 and over.
Awaiting answer.
What estimate his Department has made of the cost to the NHS of shingles-related GP appointments, A&E attendances and hospital admissions among adults aged 80 and over between the Joint Committee on Vaccination and Immunisation’s November 2024 advice on expanding eligibility and the date on which that advice is implemented.
Awaiting answer.
How many Named Day Written Parliamentary Questions to his Department were overdue for a substantive answer at the end of the 2024–26 Parliamentary Session.
Awaiting answer.
What the average number of days overdue was for Named Day Written Parliamentary Questions to his Department which were overdue for a substantive answer at the end of the 2024–26 Parliamentary Session.
Awaiting answer.
Whether his Department plans to introduce transitional or grandfathering arrangements for students who enrolled before the passage of the Medical Training (Prioritisation) Act 2026 on UK-awarded medical degrees delivered outside the British Islands.
Awaiting answer.
When his Department plans to publish guidance on the eligibility criteria for priority status under section 4 of the Medical Training (Prioritisation) Act 2026 for students graduating with UK-awarded medical degrees delivered outside the British Islands.
Awaiting answer.
Whether patients who have waited longer than 18 weeks for consultant-led elective treatment have a right to request transfer to an alternative NHS or NHS-funded independent-sector provider able to treat them sooner.
Awaiting answer.
Whether (a) statutory and (b) policy rules prevent NHS funding for an elective procedure being combined with a patient contribution to meet the cost of treatment by an independent-sector provider.
Awaiting answer.
What discussions his Department has had with the (a) Care Quality Commission, (b) General Medical Council, (c) Medicines and Healthcare products Regulatory Agency and (b) the Secretary of State for the Home Office on the regulation of private clinics prescribing cannabis-based products for medicinal use.
Awaiting answer.
How many Written Parliamentary Questions to his Department had not received a substantive answer by the end of the 2024–26 Parliamentary Session; and what the tabling date was of the oldest such Question.
Awaiting answer.
Whether his Department has made an assessment of the effectiveness of the application of Regulation 167 of the Human Medicines Regulations 2012 to the supply of unlicensed cannabis-based products for medicinal use by private clinics.
Awaiting answer.
What estimate his Department has made of the number of patient pathways removed from referral-to-treatment waiting lists following data validation exercises in each year since 2020.
Awaiting answer.
What criteria his Department uses to determine whether a person has undertaken all or a majority of their medical training outside Ireland for the purposes of section 4 of the Medical Training (Prioritisation) Act 2026.
Awaiting answer.
How many patient pathways in the net reduction in the referral-to-treatment waiting list since 1 September 2025 were removed as a result of (a) completed treatment, (b) patient-initiated cancellation or non-attendance, (c) clinical validation and (d) administrative validation.
Awaiting answer.
What assessment his Department has made of the potential impact of the Medical Training (Prioritisation) Act 2026 on British citizens studying for UK-awarded medical degrees delivered outside the British Islands.
Awaiting answer.
What steps integrated care boards are required to take when a patient awaiting consultant-led elective treatment has waited longer than 18 weeks from referral to treatment.
Awaiting answer.
With reference to the Answer of 15 January 2026 to Question 82954 on Surgery: Waiting Lists, what payments NHS England and his Department have made for waiting-list data validation exercises since 1 September 2025; and what payments have been made in the 2025–26 financial year.
Awaiting answer.
What estimate his Department has made of the number of students enrolled before the passage of the Medical Training (Prioritisation) Act 2026 on UK-awarded medical degrees delivered outside the British Islands who will not receive priority status for the UK Foundation Programme.
Awaiting answer.
What steps his Department has taken to ensure the safe prescribing of cannabis-based products for medicinal use.
Awaiting answer.
How many investigations the Medicines and Healthcare products Regulatory Agency has opened into the (a) advertising and (b) promotion of unlicensed cannabis-based products for medicinal use by private clinics since 1 January 2020; and how many have resulted in enforcement action.
Awaiting answer.